SCHEMBL2897663

SCHEMBL2897663

COc1cc(OC)nc(-n2c(=S)[nH]c3cc(C(=O)NCc4cccc(Cl)c4)c(C)cc3c2=O)n1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 1/20 0.45
▸ KMT2A Q03164 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ POLB P06746 2/20 0.44
▸ HCRTR1 O43613 1/20 0.44
▸ APEX1 P27695 1/20 0.43
▸ RXFP1 Q9HBX9 3/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ RAB9A P51151 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ EGLN3 Q9H6Z9 1/20 0.40
▸ MALT1 Q9UDY8 1/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ DYRK1B Q9Y463 1/20 0.40
▸ USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2903434 0.91 EGLN3 (0.49) KMT2AMEN1POLBRXFP1MAPT
SCHEMBL2897673 0.89 MEN1 (0.57) KMT2AMEN1POLBRXFP1KDM4E
SCHEMBL2917064 0.85 EGLN3 (0.58) PDE10AKMT2AMEN1HCRTR1RXFP1
SCHEMBL2901676 0.80 PDE10A (0.48) PDE10AKMT2AMEN1POLBAPEX1
SCHEMBL2897657 0.79 EGLN3 (0.46) PDE10AKMT2AMEN1POLBAPEX1
SCHEMBL2895423 0.79 USP2 (0.57) KMT2AMEN1POLBRXFP1ALDH1A1
SCHEMBL2915582 0.79 MEN1 (0.57) KMT2AMEN1POLBRXFP1KDM4E
SCHEMBL2894984 0.79 EGLN3 (0.59) PDE10AKMT2AMEN1APEX1RXFP1
SCHEMBL2895002 0.78 PDE10A (0.46) PDE10AKMT2AMEN1POLBAPEX1
SCHEMBL2918091 0.78 EGLN3 (0.59) PDE10AKMT2AMEN1APEX1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US claimed
EP-2240178-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-10-20 — — EP claimed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 — — WO claimed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298324-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 PDE10A 2458/4885KMT2A 395/4885MEN1 4104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback